1. Generics Bulletin
  2. >>Products

Henlius Builds On Abbott Biosimilar Partnership Gaining 69 Emerging Markets

Launches Of The First Molecules Are Expected In 2027

 
• By Urtė Fultinavičiūtė

Henlius casts a wider net for its biosimilars presence by locking in a fresh deal with the already-established partner Abbott. Also, the Chinese biosimilars developer has joined the Biosimilars Forum, securing its footing in the US.

Concept of business expansion with a person putting new location pins on a globe
(Shutterstock)

Shanghai Henlius Biotech has signed another product license and supply agreement with Abbott, providing exclusive or semi-exclusive commercialization licenses for four “self-developed” biosimilars and one biologic.

This deal opens the door for Henlius to 69 emerging markets in Asia, the Middle East, Africa, Latin America, and the Caribbean.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Business